Published in
Springer Nature [academic journals on nature.com], Pharmacogenomics Journal, 1(18), p. 127-135, 2016
DOI: 10.1038/tpj.2016.90
Links
- Springer Nature [academic journals on nature.com] | PDF
- [eprints.gla.ac.uk]
- [eprints.gla.ac.uk] | PDF
- [eprints.gla.ac.uk] | PDF
- [dash.harvard.edu] | PDF
- [www.ncbi.nlm.nih.gov] | PDF
- [europepmc.org] | PDF
Tools
Large-scale pharmacogenomic study of sulfonylureas and the QT, JT and QRS intervals: CHARGE Pharmacogenomics Working Group
,
A. V. Smith,
S. M. Gogarten,
J. Li,
L. Broer,
D. S. Evans,
S. Trompet,
J. A. Brody,
J. D. Stewart,
J. D. Eicher,
A. A. Seyerle
and other authors.
Full text: Download
Abstract
Sulfonylureas, a commonly used class of medication used to treat type 2 diabetes, have been associated with an increased risk of cardiovascular disease. Their effects on QT interval duration and related electrocardiographic phenotypes are potential mechanisms for this adverse effect. In 11 ethnically diverse cohorts that included 71 857 European, African-American and Hispanic/Latino ancestry individuals with repeated measures of medication use and electrocardiogram (ECG) measurements, we conducted a pharmacogenomic genome-wide association study of sulfonylurea use and three ECG phenotypes: QT, JT and QRS intervals. In ancestry-specific meta-analyses, eight novel pharmacogenomic loci met the threshold for genome-wide significance (P